miR-223 Overexpression is Associated with Increased Expression of EGFR and Worse Prognosis in Indonesian TNBC Patients

¹Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of M ²Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr Sardjito Hospital, Yogyakarta, Indonesia ³Department of Surgery, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr Sardjito Hospital, Yogyakarta, Indonesia ⁴ Department of Histology and Cell Biology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr Sardjito Hospital, Yogyakarta, Indonesia

Background

Triple negative breast cancer (TNBC) is associated with more aggressive disease and worse survival compared to other breast cancer subtypes. We aim to analyze the role of oncogenic microRNA-223 (miR-223) as a possible negative driving factor in TNBC through its association with clinicopathologic characteristic and prognostic value.

Methods

We retrospectively analyzed the association of pretreatment miR-223 expression with clinicopathologic characteristics and 3-years overall survival (OS) of TNBC patients treated in a tertiary center during 2014-2017. miR-223 level of tumor tissue was measured using quantitative real-time polymerase chain reaction (qRT-PCR). Cutoff value for miR-223 was determined using Receiver Operating Curve (ROC). Chi-square and Fisher's exact tests were used to analyze the association between categorical variables, while Kaplan-Meier curve was used for survival analysis.

Results

Fifty-three stage I-IV TNBC patients were included in the analysis (Table 1). The optimal cutoff value for miR-223 was 23.435 (Figure 1, Table 2) and was used to classify miR-223 expression into over- and under-expressed groups. miR-223 overexpression was associated with increased expression of Epidermal Growth Factor Receptor (EGFR) (69.7% vs. 35%, p: 0.022) and lower 3-years OS (33.3% vs. 70%; median OS±SE (months): 25.66±1.58 vs. 30.23±1.99; p log rank: 0.029) as seen in Figure 2. No significant association was observed between miR-223

Purwanto I^{1*}, Heriyanto DS², Widodo I², Hutajulu SH¹, Hardiyanti MS¹, Kurnianda J¹, Taroeno-Hariadi KW¹, Leo B¹, Satiti AD¹, Purwanto RY¹, Qurania KR¹, Aryandono T³, Haryana SM⁴

expression with other clinicopathologic characteristics (age, BMI, stage, tumor size, nodal status, distant metastasis, and CK5/6 expression).				
Characteristics		MiR-223 Underexpressed (N: 20)	Mir-223 Overexpressed (N: 33)	<i>p</i> - Value
Age	<50 y.o	6	17	p: 0.126
	≥50 y.o	14	16	
BMI	<25	11	23	p: 0.279
	≥25	9	10	
Stage	Early	3	4	p: 0.209
	LABC	16	22	
	Metastatic	1	7	
Tumor Size (T)	< 5 cm	4	9	p:0.555
	≥ 5 cm	16	24	
Nodal Status (N)	Positive	12	24	p: 0.336
	Negative	8	9	
Distant Metastasis (M)	Present	1	7	p: 0.113
	Absent	19	26	
CK5/6	Positive	10	20	p: 0.57
	Negative	10	13	
EGFR	Positive	7	23	p: 0.013
	Negative	13	10	

Table 1. Patient Clinicopathologic Profile According to MiR-223 Expression.




Figure 1. Area under curve (AUC): 0.706, 95%CI: 0.565-0.848; p: 0.01; Sensitivity: 78.6%; Specificity: 56%.




Figure 2. 3-years OS based on miR-223 expression (p log rank: 0.029).

Discussion

MiR-223 is known to have pleiotropic effect in malignancy, meaning it can act both as an oncogenic-microRNA (oncomiR) or as a tumor suppressor, depending on the context.¹ In our cohort, miR-223 was observed to have oncogenic effect which is consistent with the only existing clinical study which showed elevated level of serum miR-223 in relapsing TNBC patients compared to non-relapsing group.² Our finding, however, differs from published preclinical studies which considered miR-223 as tumor suppressor in TNBC cell lines.^{3,4} Further analysis is required



understand the mechanism behind the negative prognostic effect of miR-223 in our cohort.

Conclusion

Pre-treatment miR-223 level of expression in Indonesian TNBC patients is correlated with poor survival and increased of EGFR expression. Thus, targeting miR-223 becomes a potential therapeutic strategy for TNBC patients. However, further study is needed to validate this result.

References

- 1. Gao Y, Lin L, Li T, Yang J, Wei Y. The role of miRNA-223 in cancer: Function, diagnosis and therapy. Gene. 2017 Mar; 616: 1-7.
- 2. Sahlberg KK, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res. 2015 Mar; 21(5):1207-14.
- 3. Sun X, Li Y, Zheng M, Zuo W, Zheng W. MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1. PLoS One. 2016; 11(9): e0162754.
- . Yoshikawa M, Iinuma H, Umemoto Y, Yanagisawa T, Matsumoto A, Jinno H. Exosome-encapsulated microRNA-223-3p as a minimally invasive biomarker for the early detection of invasive breast cancer. Oncol Lett. 2018 Jun; 15(6): 9584–92.

Acknowledgements & Disclosure

The authors express gratitude to Dr. Sardjito General Hospital for providing the necessary assistance during data procurement for this publication.

The authors declare no conflicts of interest.